Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has issued an announcement.
Recce Pharmaceuticals Ltd. announced positive preclinical results for its synthetic anti-infective, RECCE® 327, in treating hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter baumannii in mice models. The study demonstrated that nebulised R327 significantly reduced bacterial load in the lungs, outperforming traditional antibiotics like meropenem, which face solubility challenges. This advancement highlights R327’s potential as a critical treatment option in hospital settings, particularly for drug-resistant lung infections, and underscores its versatility and efficacy in direct lung delivery.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is a company focused on developing a new class of synthetic anti-infectives. The company targets multidrug-resistant infections, particularly those acquired in hospital settings, and emphasizes innovative delivery methods like inhalation therapy for severe pulmonary infections.
Average Trading Volume: 120,773
Technical Sentiment Signal: Hold
Current Market Cap: A$120M
For detailed information about RCE stock, go to TipRanks’ Stock Analysis page.